Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Funda Meric-Bernstam

Showing results (521-530 of 643) with videos related to

Pageof 65
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
Investigational New Drugs|November 22, 2017
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experienceTakeo Fujii, Rivka R Colen, Mehmet Asim Bilen, et al.
JAMA Oncology|November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and BevacizumabReva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.
British Journal of Cancer|April 27, 2018
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancersShiraj Sen, Shumei Kato, Rishi Agarwal, et al.
Cancers|October 13, 2021
<i>RAC1</i> Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer PatientRozita Bagheri-Yarmand, Naifa L Busaidy, Elena McBeath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract CancerTimothy P DiPeri, Kurt W Evans, Stephen Scott, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2023
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical CancerJi Son, Heather Y Lin, Siqing Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
Clinical Proteomics|June 22, 2011
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast CancersBryan T Hennessy, Yiling Lu, Ana Maria Gonzalez-Angulo, et al.
Clinical Proteomics|September 13, 2011
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancerAna M Gonzalez-Angulo, Bryan T Hennessy, Funda Meric-Bernstam, et al.
Pageof 65

Showing results (521-530 of 643) with videos related to

Sort By:
Pageof 65
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Concordance between tumor tissue and plasma DNA genotyping in the NCI-MATCH trial (EAY131)Mohamed A Gouda, Filip Janku, Ying Yuan, et al.
Investigational New Drugs|November 22, 2017
Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experienceTakeo Fujii, Rivka R Colen, Mehmet Asim Bilen, et al.
JAMA Oncology|November 29, 2016
Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and BevacizumabReva K Basho, Michael Gilcrease, Rashmi K Murthy, et al.
British Journal of Cancer|April 27, 2018
Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancersShiraj Sen, Shumei Kato, Rishi Agarwal, et al.
Cancers|October 13, 2021
<i>RAC1</i> Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer PatientRozita Bagheri-Yarmand, Naifa L Busaidy, Elena McBeath, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2024
Utilizing Patient-Derived Xenografts to Model Precision Oncology for Biliary Tract CancerTimothy P DiPeri, Kurt W Evans, Stephen Scott, et al.
Journal of Immunotherapy and Precision Oncology|February 8, 2023
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical CancerJi Son, Heather Y Lin, Siqing Fu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
Clinical Proteomics|June 22, 2011
A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast CancersBryan T Hennessy, Yiling Lu, Ana Maria Gonzalez-Angulo, et al.
Clinical Proteomics|September 13, 2011
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancerAna M Gonzalez-Angulo, Bryan T Hennessy, Funda Meric-Bernstam, et al.
Pageof 65